Sarepta Therapeutics,, Inc. - SRPT STOCK NEWS

Sarepta Therapeutics (NASDAQ:SRPT) announced the grant of equity awards on May 31, 2022, as part of its 2014 Employment Commencement Incentive Plan. The company provided options to purchase 90,900 shares and 46,625 restricted stock units (RSUs) to 70 new employees. The options have an exercise price of $72.82 per share, equal to the stock's closing price on the grant date. Vesting occurs over four years for both options and RSUs, subject to continued employment.

Sarepta Therapeutics reported Q1 2022 revenues of $210.8 million, a 51% increase year-over-year, with net product revenues reaching $188.8 million. The company's three therapies contributed to this growth, particularly the ongoing success of AMONDYS 45, launched in February 2021. Despite a net loss of $105 million or $1.20 per share, this is an improvement from a loss of $167.3 million in Q1 2021. Sarepta maintains a strong cash position with over $2 billion on its balance sheet for further investments.

Sarepta Therapeutics (NASDAQ:SRPT) will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 9:20 a.m. P.T. The event will take place at the Encore Hotel in Las Vegas, Nevada, and will be webcast live on the company's investor relations website. This discussion will cover Sarepta's commitment to developing precision genetic medicine for rare diseases, as well as their extensive pipeline, which includes over 40 programs targeting Duchenne muscular dystrophy and limb-girdle muscular dystrophies. The webcast will remain archived for 90 days.

Sarepta Therapeutics (NASDAQ:SRPT) announced the granting of equity awards to 44 newly hired individuals on April 29, 2022. The awards, part of the 2014 Employment Commencement Incentive Plan, include options for 48,525 shares and 24,875 restricted stock units (RSUs). The options have an exercise price of $72.32, aligning with the company's stock closing price on the Grant Date. Vesting will occur over four years, contingent on continued employment. Sarepta continues to lead in precision genetic medicine, focusing on rare diseases like Duchenne muscular dystrophy.

Sarepta Therapeutics (NASDAQ:SRPT) will announce its first quarter 2022 financial results on May 4, 2022, after market close. A conference call is scheduled for 4:30 p.m. E.T. to discuss the results and provide a corporate update. The call can be accessed by dialing (800) 895-3361 for domestic callers or (785) 424-1062 for international participants, using the passcode SAREPTA. The call will also be available via webcast on their investor relations website.

Sarepta Therapeutics (NASDAQ:SRPT) announced the granting of equity awards to 37 new employees as part of its 2014 Employment Commencement Incentive Plan. This decision, approved by the Compensation Committee, was made under Nasdaq Listing Rule 5635(c)(4). The aggregate awards include options for 29,725 shares and 15,575 restricted stock units (RSUs), both vesting over four years, contingent upon continued employment. The options are priced at $78.12 per share, reflecting the stock's closing price on the grant date, March 31, 2022.

Sarepta Therapeutics (NASDAQ:SRPT) has opened applications for its Route 79 Scholarship Program for the 2022-2023 academic year, expanding to include scholarships for siblings of individuals with Duchenne muscular dystrophy (DMD). Up to 15 scholarships of $5,000 each will be awarded to students living with DMD, alongside 5 additional scholarships for their siblings. The program aims to support educational pursuits and will accept applications until May 13, 2022. Since its inception, it has awarded over 70 scholarships, reflecting an ongoing commitment to the Duchenne community.

Sarepta Therapeutics (NASDAQ:SRPT) will participate in three upcoming virtual investor conferences in March 2022. These include:

• Cowen 42nd Annual Health Care Conference on March 9, 2022, at 2:10 p.m. E.T.
• Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 3:20 p.m. E.T.
• Guggenheim 3rd Annual Genomic Medicines and Rare Disease Day on March 31, 2022, at 12 p.m. E.T.

The presentations will be available via live webcast on Sarepta's website and archived for 90 days. The company focuses on precision genetic medicine for rare diseases.

Sarepta Therapeutics reported a strong performance for Q4 and full-year 2021, with total revenues of $201.5 million and $701.9 million, respectively. Net product revenues rose 46% year-over-year in Q4, reaching $178.7 million, while full-year net product revenues increased by 34% to $612.4 million. The company launched its third RNA-based therapy, AMONDYS 45, and initiated pivotal trials for SRP-5051 and SRP-9001. With over $2.1 billion in cash, Sarepta expects total revenues exceeding $880 million in 2022, demonstrating a promising outlook in precision genetic medicine.